According to the latest market report published by Credence Research, Inc. “Cervical Dysplasia Diagnostic Market By Type (Diagnostic Test, Diagnostic Device) - Growth, Future Prospects, and Competitive Analysis, 2017 - 2025,” the global cervical dysplasia diagnostic market was valued at US$ 437.3 million in 2016 and is anticipated to reach US$ 791.3 million by 2025, increasing CAGR by 6.5 percent from 2017 to 2025

Market Insights

Cervical dysplasia, also known as cervical intraepithelial neoplasia (CIN), triggers abnormal cell growth that happens on the epithelial lining of the cervix. It is the precancerous condition of the cervix that is expected to advance to cervical cancer in an average of 10-15 years. There is a prevalent health problem among females. WHO and domestic governments are taking measures to provide a screening program and efficient education to encourage preventive practices among females. About 250,000 to 1 million females in the U.S. are diagnosed with cervical dysplasia every year.

Browse the full report at https://www.credenceresearch.com/report/cervical-dysplasia-diagnostic-market

The maximum incidence in females varies from 25-35 years of age and, if not diagnosed or treated at the earliest, in 30-40 percent of instances, invasive cancer may develop. Cervical cancer is a worldwide burden, particularly in developing nations where it is the most prevalent cause of preventable cancer-related mortality. As a result, the increasing incidence of cervical dysplasia and the development of diagnostic technology and therapy options are important factors contributing to the development of the cervical dysplasia diagnostic industry.

The worldwide market for diagnostic cervical dysplasia is segmented into diagnostic test and diagnostic devices by type of diagnosis. Diagnostic test kinds are further segmented into HPV, Pap and Biopsy tests.

As in the present business situation, North America dominates the worldwide market for diagnostic cervical dysplasia followed by Europe. Rising incidence of cervical dysplasia, progress in diagnostic technology, awareness of cervical cancer and accessible novel therapy options are some of the key variables driving the development of the cervical dysplasia diagnostic industry in North America and Europe. Asia Pacific is the fastest-growing regional market for cervical dysplasia with the largest CAGR in the forecast period.

Download Free PDF Sample Request: https://www.credenceresearch.com/sample-request/58678

Market Competition Assessment:

Key players in the global cervical dysplasia diagnostic market are Abbott Laboratories, Becton, Dickinson and Company, F. Hoffmann La-Roche Ltd., GlaxoSmithKline Plc, Helix BioPharma Corp., Hologic, Inc., Inovio Biomedical Corporation, Micromedic Technologies Ltd., OncoHealth Corporation, PDS Biotechnology Corporation, Photocure ASA, Quest Diagnostics, Inc., QIAGEN N.V. and others.

Key Market Movements:

Increase in incidence and mortality of cervical cancer is leading to global burden especially in developing countries. In developed countries government is taking initiatives for screening programs with goal of early diagnosis and treatment of cervical dysplasia which play pivotal role in growth of cervical dysplasia diagnostic market.
Advancement in diagnostic technology and novel drug treatment option available in market would further propel the growth of cervical dysplasia diagnostic market.
Report Scope by Segments

By Type of Diagnosis

Diagnostic Test
HPV Test
Pap Smear Test
Biopsy
Diagnostic Device
Colposcopy
By Geography Segment

North America
Europe
Asia Pacific (APAC)
Middle East & Africa (MEA)
Latin America
Medium Blog: https://medium.com/@kumarganesh028/cervical-dysplasia-diagnostic-market-6-5-ccb44a20fce2